Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
By Lee Jackson January 7, 2014
Celldex Therapeutics Inc. (NASDAQ: CLDX) focuses on developing therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines. Investors are interested in Celldex because of the unmet need therapies the company is developing. Celldex is working on drug indications that include therapies for glioblastoma, breast cancer, dense deposit disease and lymphoma. A recent secondary stock offering helped shore up the company coffers. The company is to update its CDX-1135 drug status, which could be a huge catalyst. The Oppenheimer price target is set at $40. The Thomson/First Call estimate is in line at $39.
Best Social-Network Stock: Facebook, Twitter, or LinkedIn?
By Andrés Cardenal | More Articles | Save For Later
January 5, 2014
Twitter is becoming a leading global communications platform. Not only do users access all kinds of information and news on the network, but traditional media outlets are also increasingly paying more attention to what goes on at Twitter. The company allows people to expand their voice and reach, and also to communicate and interact with their favorite actors, sports stars, political leaders, journalists, or companies.
Each user's experience is highly personalized, depending on areas of interest and how people build their networks, interact among each other, and post their own content. This allows the company to collectenormously valuable information, which it can then use to efficiently target advertising to the right people at the right time.
Article :Stock Market Today: An Apple Downgrade and a Twitter Upgrade
By Demitrios Kalogeropoulos | More Articles | Save For Later
January 2, 2014
Evercore sees a shift in online video content under way that Twitter shouldbenefit from by grabbing billions in new ad revenue over the next few years.
By: Tom Meyer
12/27/2013 @ 12:22PM
The Race To Develop A Brain Cancer Treatment Takes An Interesting Turn
Given the remarkable results that aldoxorubicin demonstrated in 1st-Line STS, it’s hard not to believe that something similar could be in store for the Phase 2 GBM trial. CytRx certainly appears poised for a significant run in the months and years ahead as the company’s platform continues to be validated by science. But before taking a position, investors should take a look at the company’s finances as well.
As of the end of the third quarter, CytRx had approximately $23 million in available cash and short-term investments. That amount does not include the $25.9 million (less fees) that the company raised from its October offering. Given the company’s monthly burn rate of about $2 million, the company’s cash balance should be sufficient to fund operating expenses well into 2015 (at a minimum). CytRx Corporation appearsto be an extremely compelling investment story and investors may want to consider taking a position before the share price really starts to take off